Literature DB >> 24590058

STAT3-mediated autophagy dependence identifies subtypes of breast cancer where autophagy inhibition can be efficacious.

Paola Maycotte1, Christy M Gearheart, Rebecca Barnard, Suraj Aryal, Jean M Mulcahy Levy, Susan P Fosmire, Ryan J Hansen, Michael J Morgan, Christopher C Porter, Daniel L Gustafson, Andrew Thorburn.   

Abstract

Autophagy is a protein and organelle degradation pathway that is involved in diverse diseases, including cancer. Recent evidence suggests that autophagy is a cell survival mechanism in tumor cells and that its inhibition, especially in combination with other therapy, could be beneficial but it remains unclear if all cancer cells behave the same way when autophagy is inhibited. We inhibited autophagy in a panel of breast cancer cell lines and found that some of them are dependent on autophagy for survival even in nutrient rich conditions without any additional stress, whereas others need autophagy only when stressed. Survival under unstressed conditions is due to cell type-specific autophagy regulation of STAT3 activity and this phenotype is enriched in triple-negative cell lines. This autophagy-dependency affects response to therapy because autophagy inhibition reduced tumor growth in vivo in autophagy-dependent but not in autophagy-independent breast tumors, whereas combination treatment with autophagy inhibitors and other agent was preferentially synergistic in autophagy-dependent cells. These results imply that autophagy-dependence represents a tumor cell-specific characteristic where autophagy inhibition will be more effective. Moreover, our results suggest that autophagy inhibition might be a potential therapeutic strategy for triple-negative breast cancers, which currently lack an effective targeted treatment. ©2014 AACR.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24590058      PMCID: PMC4008672          DOI: 10.1158/0008-5472.CAN-13-3470

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  46 in total

Review 1.  Autophagy: renovation of cells and tissues.

Authors:  Noboru Mizushima; Masaaki Komatsu
Journal:  Cell       Date:  2011-11-11       Impact factor: 41.582

2.  Dual functions of autophagy in the response of breast tumor cells to radiation: cytoprotective autophagy with radiation alone and cytotoxic autophagy in radiosensitization by vitamin D 3.

Authors:  Molly L Bristol; Xu Di; Matthew J Beckman; Eden N Wilson; Scott C Henderson; Aparna Maiti; Zhen Fan; David A Gewirtz
Journal:  Autophagy       Date:  2012-04-13       Impact factor: 16.016

Review 3.  Deconvoluting the context-dependent role for autophagy in cancer.

Authors:  Eileen White
Journal:  Nat Rev Cancer       Date:  2012-04-26       Impact factor: 60.716

4.  Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells.

Authors:  Rekha Rao; Ramesh Balusu; Warren Fiskus; Uma Mudunuru; Sreedhar Venkannagari; Lata Chauhan; Jacqueline E Smith; Stacey L Hembruff; Kyungsoo Ha; Peter Atadja; Kapil N Bhalla
Journal:  Mol Cancer Ther       Date:  2012-02-24       Impact factor: 6.261

5.  The expression of the receptor for advanced glycation endproducts (RAGE) is permissive for early pancreatic neoplasia.

Authors:  Rui Kang; Tara Loux; Daolin Tang; Nicole E Schapiro; Philip Vernon; Kristen M Livesey; Alyssa Krasinskas; Michael T Lotze; Herbert J Zeh
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-16       Impact factor: 11.205

Review 6.  Breast cancer statistics, 2011.

Authors:  Carol DeSantis; Rebecca Siegel; Priti Bandi; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2011-10-03       Impact factor: 508.702

7.  Punctate LC3B expression is a common feature of solid tumors and associated with proliferation, metastasis, and poor outcome.

Authors:  Rossitza Lazova; Robert L Camp; Vincent Klump; Summar F Siddiqui; Ravi K Amaravadi; John M Pawelek
Journal:  Clin Cancer Res       Date:  2011-11-11       Impact factor: 12.531

8.  Atg7 modulates p53 activity to regulate cell cycle and survival during metabolic stress.

Authors:  In Hye Lee; Yoshichika Kawai; Maria M Fergusson; Ilsa I Rovira; Alexander J R Bishop; Noboru Motoyama; Liu Cao; Toren Finkel
Journal:  Science       Date:  2012-04-13       Impact factor: 47.728

Review 9.  Autophagy modulation as a potential therapeutic target for diverse diseases.

Authors:  David C Rubinsztein; Patrice Codogno; Beth Levine
Journal:  Nat Rev Drug Discov       Date:  2012-09       Impact factor: 84.694

10.  Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia.

Authors:  C C Porter; J Kim; S Fosmire; C M Gearheart; A van Linden; D Baturin; V Zaberezhnyy; P R Patel; D Gao; A C Tan; J DeGregori
Journal:  Leukemia       Date:  2012-01-13       Impact factor: 11.528

View more
  69 in total

1.  Basal autophagy is negatively regulated by RIP1.

Authors:  Michael J Morgan
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

Review 2.  Identifying and targeting tumor-initiating cells in the treatment of breast cancer.

Authors:  Wei Wei; Michael T Lewis
Journal:  Endocr Relat Cancer       Date:  2015-04-15       Impact factor: 5.678

3.  RIP1 negatively regulates basal autophagic flux through TFEB to control sensitivity to apoptosis.

Authors:  Tohru Yonekawa; Graciela Gamez; Jihye Kim; Aik Choon Tan; Jackie Thorburn; Jacob Gump; Andrew Thorburn; Michael J Morgan
Journal:  EMBO Rep       Date:  2015-04-23       Impact factor: 8.807

4.  The Challenge of Developing Autophagy Inhibition as a Therapeutic Strategy.

Authors:  David A Gewirtz
Journal:  Cancer Res       Date:  2016-09-15       Impact factor: 12.701

Review 5.  Autophagy, cancer stem cells and drug resistance.

Authors:  Alexandra G Smith; Kay F Macleod
Journal:  J Pathol       Date:  2019-02-04       Impact factor: 7.996

6.  Autophagy-dependent cancer cells circumvent loss of the upstream regulator RB1CC1/FIP200 and loss of LC3 conjugation by similar mechanisms.

Authors:  Christina G Towers; Darya Wodetzki; Andrew Thorburn
Journal:  Autophagy       Date:  2020-03-18       Impact factor: 16.016

7.  Autophagy inhibition re-sensitizes pulse stimulation-selected paclitaxel-resistant triple negative breast cancer cells to chemotherapy-induced apoptosis.

Authors:  Jian Wen; Syn Yeo; Chenran Wang; Song Chen; Shaogang Sun; Michael A Haas; Wei Tu; Feng Jin; Jun-Lin Guan
Journal:  Breast Cancer Res Treat       Date:  2015-02-01       Impact factor: 4.872

Review 8.  Targeting autophagy in breast cancer.

Authors:  Paola Maycotte; Andrew Thorburn
Journal:  World J Clin Oncol       Date:  2014-08-10

Review 9.  Targeting autophagy in cancer.

Authors:  Jean M Mulcahy Levy; Christina G Towers; Andrew Thorburn
Journal:  Nat Rev Cancer       Date:  2017-07-28       Impact factor: 60.716

10.  Design, Synthesis, and Characterization of an Orally Active Dual-Specific ULK1/2 Autophagy Inhibitor that Synergizes with the PARP Inhibitor Olaparib for the Treatment of Triple-Negative Breast Cancer.

Authors:  Huiyu Ren; Nicole A Bakas; Mitchell Vamos; Apirat Chaikuad; Allison S Limpert; Carina D Wimer; Sonja N Brun; Lester J Lambert; Lutz Tautz; Maria Celeridad; Douglas J Sheffler; Stefan Knapp; Reuben J Shaw; Nicholas D P Cosford
Journal:  J Med Chem       Date:  2020-11-17       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.